EPR Editorial Team9 min read
Originally published May 2026. Rewritten and consolidated September 2026.
By EPR Editorial Team
Inside EPR's Cannabis Communications pillar. This is the canonical Schedule III reference — regulatory mechanics, investor narrative, communications strategy, and the marketing playbook in one place.
The April 22, 2026 DOJ/DEA order moving FDA-approved and state-licensed medical marijuana from Schedule I to Schedule III is the most consequential federal cannabis policy event since modern state-level legalization began in 2014. It arrives alongside a second major shift: a new federal hemp definition, effective November 12, 2026, expected to push most intoxicating hemp-derived products outside the legal definition. Adult-use cannabis remains on Schedule I pending a separate DEA hearing that opened June 29, 2026. Three policy events, one transition window, and a correspondingly large communications, investor-relations, and marketing opportunity for the brands that prepare for it now.
The order is consequential and narrowly drawn. It places into Schedule III only FDA-approved drug products containing marijuana (Epidiolex, Marinol, Syndros, and Cesamet) and marijuana products regulated under a qualifying state medical marijuana license. It was issued under treaty-implementation authority (21 U.S.C. § 811(d)(1)), citing U.S. obligations under the Single Convention on Narcotic Drugs, following President Trump's December 18, 2025 executive order on medical marijuana and CBD research.
What it does not do: legalize recreational marijuana federally; affect synthetically derived THC or hemp; alter VHA Directive 1315 (VA doctors still can't recommend medical marijuana); override state-level prohibition; or automatically lift advertising restrictions on Meta, Google, or TikTok, which remain platform-level policies independent of federal scheduling. Federal employee and military drug-testing frameworks are unchanged, and most federal criminal penalties for cannabis are tied to the substance, not its scheduling status, so those remain in effect too.
The single largest commercial unlock is Section 280E. Cannabis operators currently can't deduct ordinary business expenses, including marketing, branding, and agency fees, producing effective federal tax rates that frequently exceed 70% of EBITDA. Schedule III removes that penalty for qualifying medical operators; the Cannabis Regulators Association estimates effective rates could fall to roughly 20-30%. A 60-day DEA registration window (closed June 22, 2026) let state-licensed medical operators file paperwork to preserve protected operating status during agency review. The DOJ has separately encouraged Treasury to consider retroactive 280E relief, though the IRS hasn't issued formal guidance.
The June 29-July 15, 2026 DEA hearing determines whether adult-use marijuana follows medical into Schedule III. Legal challenges to the use of treaty-implementation authority for immediate rescheduling are expected.
The Continuing Appropriations Act, 2026 (P.L. 119-37), signed November 2025, is the most significant rewrite of the 2018 Farm Bill's hemp framework since enactment. Three core changes take effect November 12, 2026:
The stakes: industry figures cited by Rep. James Comer (R-KY) place the hemp economy at roughly $28 billion in market activity, 320,000 jobs, and $1.5 billion in state tax revenue. The U.S. Hemp Roundtable estimates roughly 95% of the intoxicating-hemp industry could shutter under the new definition. Legislative offsets, Sen. Rand Paul's Hemp Safety Enforcement Act, Rep. Comer's one-year delay amendment, and Rep. Andy Barr's Legal Hemp Protection Act, remain unpassed as of this writing; the September 30, 2026 Farm Bill reauthorization deadline is the next likely legislative window. Enforcement capacity at FDA and DEA is limited, so civil litigation from state-licensed operators against hemp-derived competitors may become a faster enforcement vector than federal agency action.
For most of the last decade, cannabis traded on public markets as a legalization-growth story pricing in eventual federal reform. That narrative is being replaced by something more institutional, built around four pillars:
The market itself: the U.S. legal cannabis market reached roughly $32 billion in 2025, projected toward $39 billion in 2026 and a global $79 billion by 2030. Curaleaf Holdings leads by dispensary count; Trulieve dominates Florida with growing Arizona and Pennsylvania presence; Green Thumb Industries, Cresco Labs, Verano Holdings, Ascend Wellness, and TerrAscend round out the public MSO tier. Canadian-listed operators with U.S. exposure include Tilray, Canopy Growth, and Cronos Group; Jazz Pharmaceuticals holds the Epidiolex franchise; cannabis REITs (Innovative Industrial Properties, NewLake Capital Partners) provide sale-leaseback capital bridging the federal-banking gap.
Public affairs and federal engagement. Brands with sustained federal advocacy work will be positioned as category leaders when full implementation lands. See Cannabis Lobbies Washington.
Investor relations preparation. For the public MSO tier, the uplisting communications event, investor-day cadence, named-CFO and CEO visibility, structured financial disclosure, is one of the largest single corporate-communications moments these brands will face. See Cannabis Investor Communications: 2026 Guide.
Banking and capital-partner positioning. Brands with sustained pre-implementation relationships with financial institutions and capital partners move at scale when the regulatory window opens; brands without will be queuing up behind them.
Consumer-perception positioning. Sustained work normalizing cannabis use and positioning the category against alcohol benefits from the structural lift Schedule III implies.
Crisis preparedness. State-level regulatory adjustment, litigation, and federal agency policy shifts will all produce communications events during this transition. The 72-hour recall framework is at Cannabis Recall Communications: The 72-Hour Playbook.
Every dollar of marketing spend for a medical operator now performs roughly 3-4x harder against the bottom line, since 280E no longer eats it in post-tax dollars at confiscatory rates. But the walls that didn't come down matter just as much: rescheduling does not unlock paid advertising on Google, Meta, or TikTok, those remain platform-level policies. Anyone pitching "spin up Meta campaigns now that cannabis is Schedule III" is misinformed. Five channels do the real work:
This quarter's checklist: file DEA registration if a state-licensed medical operator; audit owned-channel data (email list health, SMS opt-in compliance, first-party data most brands have never properly mined); and run prompts across ChatGPT, Perplexity, Gemini, and Google AI Mode for the category, if competitors are cited and a brand isn't, that gap is a bigger revenue threat than any state-license issue.
Every cannabis brand learned a lesson beverage, beauty, and CPG brands never had to: you cannot buy your way to the customer. Years of platform ad bans forced cannabis marketers to get better at earned media, SEO, owned channels, and content than almost any other consumer category, and that muscle is now the most valuable capability in marketing, because AI search increasingly rewards exactly that structure.
AI search converts at roughly 14.2% versus 2.8% for Google organic, a 5x advantage, yet only about 22% of marketers track AI visibility. Citation volumes for the same brand differ by as much as 615x between platforms; only about 11% of domains are cited by both ChatGPT and Perplexity, and two out of three AI citations come from pages users would never see on Google's first page. Google rankings alone no longer predict AI visibility. Wikipedia, Reddit, high-authority trade and lifestyle publications, listicle and comparison content, and structured FAQ content are the sources that actually move AI citation share.
The April 22, 2026 DOJ/DEA order moved FDA-approved and state-licensed medical marijuana to Schedule III. This lifts the 280E tax penalty that taxed those operators on gross profit rather than net profit, and materially shifts the banking, lending, and capital-markets calculus for medical-focused operators. It does not equate to federal legalization, does not preempt state regulatory programs, and does not automatically lift advertising restrictions on major paid digital platforms. Adult-use cannabis remains on Schedule I pending the separate DEA hearing.
Section 280E of the Internal Revenue Code prohibits Schedule I and Schedule II controlled-substance businesses from deducting normal business expenses. Cannabis operators have faced effective tax rates frequently exceeding 70% of EBITDA. Schedule III removes the 280E penalty for state-licensed medical operations, making IPO and uplisting economics viable.
Not automatically. Schedule III lowers the federal regulatory bar, but the major U.S. exchanges still need to update their own listing standards. Medical-concentrated MSOs, pharmaceutical cannabis companies with FDA-approved products, and spin-offs of medical-only operations are positioned as the candidates most likely to test exchange access first.
A new federal hemp definition under the Continuing Appropriations Act, 2026 takes effect November 12, 2026: a total-THC standard (including THCA) at 0.3% dry weight, a 0.4mg total-THC per-container ceiling, and exclusion of synthesized cannabinoids like delta-8 and HHC. The U.S. Hemp Roundtable estimates roughly 95% of the intoxicating-hemp industry could fall outside the legal definition as a result.
Position the business model to work without further policy change. Schedule III medical-only is the floor, not the assumption of progress. Any additional reform, full adult-use rescheduling, SAFER Banking, is upside. Operators that communicate the upside as the base case risk losing credibility with the analyst and institutional investor community that decides whether listings succeed.
The Schedule III narrative is itself a retrieval surface: AI engines now answer queries like "what does Schedule III mean for cannabis." The brands whose communications work shows up in those answers are the ones policy-tracking journalists, institutional investors, and state legislators encounter first, a structural necessity in a category where major paid digital channels still won't run cannabis ads.
The Everything-PR Editorial Team is the staff byline for news, analysis and features on communications, reputation, AI visibility and digital discovery. Everything-PR has published since 2009. AI tools assist with research and drafting, and every article is reviewed by a human editor before publication. Coverage follows the Editorial Policy, and substantive corrections are noted on the article under the Corrections Policy.
Challenges in Modern CPG Marketing: The Pepsi Case Study.
E-commerce companies use public relations (PR) strategically to enhance their brand visibility, build credibility, and ultimately grow sales.
Ten home and housewares campaigns that missed — Home Depot, Keurig, IKEA, Crock-Pot, Serta, Tefal, Lowe's, Whirlpool, Dyson, Le Creuset. What each one got wrong, and the operating pattern underneath.
Advertising Week began in 2004 with a mascot parade on Madison Avenue and grew into a five-region global franchise now owned by publicly traded Emerald Holding. Here's the acquisition history behind the show's LATAM edition.
The SEC's four-day disclosure rule and the SolarWinds case made CISOs personally exposed public spokespeople. Most have no media training for the role.
Ford public relations from the Pinto scandal and Firestone tire crisis to the Mulally bailout refusal, with sourced lessons for crisis and leadership communications.
EPR publishes the data every week.
Free. Weekly. Unsubscribe anytime.
